The short version of incretin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Hazard research is published: a study demonstrates that exposure to microplastics causes neurobehavioral and immunological changes in mammals (mice), varying by age (1 Aug), a study shows people can't reliably detect speech deepfakes with detection for years-old AI software being at 73% (2 Aug), researchers report an unprecedented accuracy of reading keystrokes from audio of smartphone-recordings or video-chats (7 Aug), a global survey study of climate policy researchers finds these experts substantially doubt the prevailing green growth narrative, "underscor[ing] the importance of considering alternative post-growth perspectives" that include approaches of agrowth and degrowth (7 Aug), a study investigating results from a GBD study finds that while age-standardized number of cardiovascular deaths from PM air pollution have declined during the past three decades, all-age DALYs increased by 31%, reaching ~89 million years in 2019, to which years of potential life lost contributed the most with ~82 million years lost during this year (9 Aug), a study indicates a third of men worldwide are infected with genital human papillomavirus which is relevant to cancer prevention, long-term sequelae and vaccination (16 Aug), a preprint confirms smart bulbs may often be one of the weakest links that can be used to gain access to a nearby person's Wi-Fi network (17 Aug), a GBD study projects cure-less osteoarthritis to affect nearly one billion people by 2050 (21 Aug), a study indicates that all types of straws, including paper straws, except for those made of stainless steel and few exceptions, expose people and their environments to PFAS (24 Aug), a study indicates cannabis is often a source of exposure to the contaminants cadmium and lead (30 Aug), researchers demonstrate Web browser extensions can gather passwords from input fields of many of the largest websites (30 Aug). Promising results of health and medical research are reported: mice- and dogs-tested AOH1996 against cancer growth and for combination with other anti-cancer agents (1 Aug), a mice-tested engineered probiotic against autoimmunity in the brain as in multiple sclerosis (9 Aug), mice-tested engineered bacteria to detect cancer DNA (10 Aug), a review finds that of the compared insecticide-treated nets to prevent malaria, chlorfenapyr-pyrethroid – or PNP combinations – are overall the most effective and address insecticide-resistance (16 Aug), mice-tested clovibactin against antibiotic-resistant bacterial pathogens (22 Aug), two brain implants achieve milestone performances in words per minute and median word error rate (23 Aug), mice-tested phytosterols – or cholesterol-imbalance-correction more broadly – against aging-associated hearing loss (24 Aug), a pig-tested artificial kidney transplant containing a bioreactor containing renal cells for renal replacement therapy (29 Aug), a Raman-based first test for diagnosing ME/CFS and differentiating between severities with potential relevance to long COVID (31 Aug).
Pantothenic acid (vitamin B5) is a B vitamin and an essential nutrient. All animals need pantothenic acid in order to synthesize coenzyme A (CoA), which is essential for cellular energy production and for the synthesis and degradation of proteins, carbohydrates, and fats. Pantothenic acid is the combination of pantoic acid and β-alanine. Its name comes from the Greek πάντοθεν pantothen, meaning "from everywhere", because pantothenic acid, at least in small amounts, is in almost all foods. Deficiency of pantothenic acid is very rare in humans. In dietary supplements and animal feed, the form commonly used is calcium pantothenate, because chemically it is more stable, and hence makes for longer product shelf-life, than sodium pantothenate and free pantothenic acid.
During the first half of the 20th century, the 129th regiment of infantry of the line was stationed at Le Havre and left an important mark on the city so a street was named after them. The 74th Infantry Regiment of commandos was present from 1963 to 1976. Finally, Le Havre is the godmother city for BPC Mistral. The ceremony was held at the City Hall on 15 November 2009, during a stopover at the Building.
Aluminum salts or gels are added as adjuvants. Adjuvants are added to promote an earlier, more potent response, and more persistent immune response to the vaccine; they allow for a lower vaccine dosage. Antibiotics are added to some vaccines to prevent the growth of bacteria during production and storage of the vaccine. Egg protein is present in the influenza vaccine and yellow fever vaccine as they are prepared using chicken eggs. Other proteins may be present. Formaldehyde is used to inactivate bacterial products for toxoid vaccines. Formaldehyde is also used to inactivate unwanted viruses and kill bacteria that might contaminate the vaccine during production. Monosodium glutamate (MSG) and 2-phenoxyethanol are used as stabilizers in a few vaccines to help the vaccine remain unchanged when the vaccine is exposed to heat, light, acidity, or humidity. Thiomersal is a mercury-containing antimicrobial that is added to vials of vaccines that contain more than one dose to prevent contamination and growth of potentially harmful bacteria. Due to the controversy surrounding thiomersal, it has been removed from most vaccines except multi-use influenza, where it was reduced to levels so that a single dose contained less than a microgram of mercury, a level similar to eating ten grams of canned tuna.
=== Victims === On 17 September 2008, Health Minister Chen Zhu stated tainted milk formula had "sickened more than 6,200 children, and that more than 1,300 others, mostly newborns, remain hospitalized with 158 suffering from acute kidney failure". By 23 September, about 54,000 children were reported to be sick and four had died. An additional 10,000 cases were reported from the provinces by 27 September. A World Health Organization official said 82% of the children made ill were 2 years of age or below. The Hong Kong Centre for Food Safety said that 99 per cent of the victims were aged under 3 years. Ten Hong Kong children were diagnosed with kidney problems, at least four cases were detected in Macau, and six in Taiwan. Non-human casualties included a lion cub and two baby orangutans which had been fed Sanlu infant formula at Hangzhou Zoo. The government said on 8 October it would no longer issue updated figures "because it is not an infectious disease, so it's not absolutely necessary for us to announce it to the public". Reuters compiled figures reported by local media across the country, and said the toll stood at nearly 94,000 at the end of September, excluding municipalities. Notably, 13,459 children had been affected in Gansu, Reuters quoted Xinhua saying Henan had reported over 30,000 cases, and Hebei also had nearly 16,000 cases. In late October, the government announced health officials had surveyed 300,000 Beijing families with children less than 3 years old.
Sources: en.wikipedia.org
=== Metabolism === The metabolism of the compound primarily occurs in the liver through both reduction and conjugation pathways. A major metabolic step involves the reduction of the quinone to its corresponding hydroquinone. The main metabolic route is the detoxification via conjugation with glutathione (GSH). This phase II metabolism reaction serves to neutralize the compound's electrophilicity, facilitating safer elimination. Nevertheless, excessive or chronic exposure may lead to the depletion of cellular GSH pools, which enhances oxidative stress and potential cellular damage. The subsequent processing of these glutathione conjugates results in the formation of cysteine conjugates and mercapturic acids.
=== Trump administration === After Harris was defeated by former president Donald Trump in the general election on November 5, 2024, Moore pledged to work with the Trump administration, but said he would push back when necessary. He also pledged to defend Marylanders' constitutional rights, and restore faith in public institutions and democracy during Trump's second presidency. By February 2025, Moore maintained that he would still be open to working with anyone to advance Maryland's interests, but expressed pessimism toward being able to partner with the Trump administration, adding that he planned to use the power of his office to counter Trump—including executive orders and backing federal litigation filed by Maryland Attorney General Anthony Brown against several of Trump's actions—and criticizing the president for dismantling federal departments, furloughing thousands of federal workers, and starting tariff wars. Moore opposed the One Big Beautiful Bill Act, calling it "one of the worst bills for working families that our country has ever proposed" and predicting that it would result in one of the largest upward transfers of wealth from the poor to the rich in American history through cuts to federal assistance programs and tax cuts for wealthy individuals and big corporations.
In March 2013, the City of Pittsburgh filed a lawsuit in Federal court challenging the tax exempt status of UPMC as a public charity, in an effort to make UPMC to pay back taxes. The city alleged that UPMC has abused its status to avoid paying property taxes. The city dropped its lawsuit in 2014. In February 2019, the Pennsylvania Attorney General submitted legal actions against UPMC to enforce requirements for open health care access based on the non-profit status of UPMC. These actions stem from a long-standing dispute between Highmark Health and UPMC, the largest two health-care providers in Western PA. In 2011, Highmark entered a partnership with West Penn Hospital System (now Allegheny Health Network). Because of this competitive threat, UPMC declared they would not accept Highmark Blue Cross Blue Shield Insurance. In order to protect public access to health care while agreements between the two systems unwound, both UPMC and Highmark Health accepted a state-brokered consent decree. With the consent decree expiring in 2019, the Pennsylvania Attorney General attempted to negotiate continued access to care with both companies. Highmark indicated that it would accept the terms while UPMC did not. It is the failure to accept the proposal that the PA Attorney General cited as leading to the legal actions of February 2019.
== Cosmetic use == Copper peptide GHK-Cu is widely used in anti-aging and hair loss prevention cosmetics (INCI name: Copper tripeptide-1). Several controlled facial studies have shown anti-aging, firming and anti-wrinkle activity of copper peptide GHK-Cu, but with relatively small sample sizes and short duration of use, and further research is required to draw definitive conclusions.
== Synthesis == There is no concrete evidence or agreement on the exact mechanisms of fibrillogenesis, however, multiple hypotheses based on primary research have put forth various mechanisms to consider. Collagen fibrillogenesis occurs in the plasma membrane during embryonic development. Collagen within the body has a denaturation temperature between 32-40 degrees Celsius, the physiological temperature also falls within this range and thereby poses a significant problem. It is not known how collagen survives within the tissues in order to yield itself to the formation of collagen fibrils. A postulated solution to the problem of denaturation, is that newly formed collagen gets stored in vacuoles. The storage vacuoles also contain molecular aggregates that provide the required thermal stability to allow for fibrillogenesis to occur within the body. In the body, fibrillar collagens have over 50 known binding partners. The cell accounts for the variety of binding partners through the localization of the fibrillogenesis process to the plasma membrane in order to maintain control of which molecules bind to each other and further ensure both fibril diversity and assemblies of certain collagen fibrils in different tissues Kader, Hill, and Canty-Larid published a plausible mechanism for the formation of collagen fibrils. Fibronectin a glycoprotein that binds to receptor proteins known as integrins within the cytoskeleton is a key player in the hypothesized method of fibrillogenesis.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.